GPCR Structure Therapeutics
- 43.490
- +1.300+3.08%
- 42.200
- -1.290-2.97%
Structure Therapeutics News
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | 8-K: Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | S-1MEF: A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S 1
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | 8-K: Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics | DEF 14A: Definitive information statements
Structure Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Structure Therapeutics | 8-K: Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Structure Therapeutics | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | 8-K: Current report
Structure Therapeutics | 8-K: Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
Structure Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
No Data
